Clinical trial
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
NCT02795156
Study timeline
Study start (actual)2016-09-28Date precision: day
Registry last updated2023-12-05
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non-small Cell Lung Carcinomaunresolved
Urothelial Carcinomaunresolved
Gastrointestinal Carcinoma, Non-colonunresolved
Upper Aerodigestive Tract Carcinomaunresolved
Interventions
AfatinibDRUG · verified · RxNorm: afatinib
RegorafenibDRUG · verified · RxNorm: regorafenib
CabozantinibDRUG · verified · RxNorm: cabozantinib
Sponsors & collaborators
SCRI Development Innovations, LLClead sponsor
Foundation Medicinecollaborator
Boehringer Ingelheimcollaborator
Bayercollaborator
Exelixiscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02795156 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.